Description:
Evofosfamide is a hypoxia-activated prodrug consisting of a 2-nitroimidazole phosphoramidate conjugate with potential antineoplastic activity. The 2-nitroimidazole moiety of hypoxia-activated prodrug TH-302 acts as a hypoxic trigger, releasing the DNA-alkylating dibromo isophosphoramide mustard moiety within hypoxic regions of tumors. Normoxic tissues may be spared due to the hypoxia-specific activity of this agent, potentially reducing systemic toxicity.
- Molecular Weight:449.04
- Melting Point:97-98°C
- Purity:> 98%
Molecular Formula:
C9H16Br2N5O4P
Canonical SMILES:
CN1C(=CN=C1[N+](=O)[O-])COP(=O)(NCCBr)NCCBr
InChI:
InChI=1S/C9H16Br2N5O4P/c1-15-8(6-12-9(15)16(17)18)7-20-21(19,13-4-2-10)14-5-3-11/h6H,2-5,7H2,1H3,(H2,13,14,19)
InChIKey:
UGJWRPJDTDGERK-UHFFFAOYSA-N
Appearance:
Off-White to Pale Yellow Solid
Synonyms:
TH-302; TH 302; TH302; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine Más detalles se encuentran
aquí